The future direction of MDMA drug developer Lykos Therapeutics is uncertain on many fronts since the FDA rejected its new drug application last Summer. Questions abound, including: What will the outcome of the independent review of its Phase 3 program be? What does the path to resubmission look like? Will the company secure the funding it needs to continue on that path? What might the priorities…
